Search

Search Constraints

You searched for: Author/Creator Beg, M.

Search Results

1. The AXL inhibitor, TP-0903, reverses EMT and shows activity in non-small cell lung cancer preclinical models. (October 2022)

2. Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC). (October 2022)